Trial Profile
Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) Retrospectively and Prospectively as First Line Treatment for Patients With Advanced or Metastatic Non Small Cell Lung Cancer. Assessment of Toxicity, Compliance and Survival of Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jul 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 23 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2013 New trial record